Abciximab

Indications
 Intravenous
Stabilisation in patients with unstable angina
Adult: 250 mcg/kg as a bolus Inj over 1 minute followed by 0.125 mcg/kg/minute (max: 10 mcg/minute) infusion. To be started up to 24 hr before and continue for 12 hr after the possible intervention.
Renal impairment: Avoid in severe renal impairment requiring dialysis.
Hepatic impairment: Avoid in severe hepatic impairment in whom coagulation may be affected.
Intravenous
Adjunct in the prophylaxis of acute ischaemic complications in percutaneous coronary intervention
Adult: 250 mcg/kg as a bolus Inj over 1 minute followed by 0.125 mcg/kg/minute (max: 10 mcg/minute) infusion. To be started 10-60 minutes before PCI and continue for 12 hr.
Renal impairment: Avoid in severe renal impairment requiring dialysis.
Hepatic impairment: Avoid in severe hepatic impairment in whom coagulation may be affected.
Contraindications
 Hypersensitivity to any component or to murine proteins; active bleeding; patients at increased risk of haemorrhage, recent (within 6 wk) GI or genitourinary bleeding of clinical significance; history of CVA (CVA) within 2 yr or CVA with a significant residual neurological deficit; bleeding diathesis; thrombocytopenia (10,000 cells/microlitre); clotting abnormalities; admin of oral anticoagulants within 7 days; recent (within 6 wk) major surgery or trauma; intracranial tumor, arteriovenous malformation or aneurysm; severe uncontrolled hypertension; severe renal or hepatic impairment presumed or documented history of vasculitis; use of IV dextran before PTCA, or intent of use during PCTA.
Warnings / Precautions
 Elderly >75 yr, recent thrombolytic therapy, unsuccessful PTCA. During readmin; use with thrombolytics, anticoagulants and other antiplatelet agents; while obtaining IV route and/or during arterial and venous punctures/intubations; measure platelet count, prothrombin time and aPTT to identify preexisting haemostatic abnormalities before admin; pregnancy, lactation; children <18 yr; patients weighing <75 kg.
Adverse Reactions
 Hypotension, bradycardia, back and chest pain, arterial fibrillation/flutter; nausea, headache, fever, vomiting; haematoma, vascular disorders, anaemia, leukocytosis; hypoesthesia, confusion, abnormal thinking, dizziness; pleural effusion/pleurisy, pneumonia; urinary tract infection; pain, peripheral oedema, abnormal vision, dysphonia, pruritus; haemolytic anaemia, petechiae.
Potentially Fatal: Bleeding (during the 1st 3 hr after admin) e.g. from GI, genitourinary; retroperitoneal; thrombocytopaenia; human anti-chimeric antibody development.
Drug Interactions
 Patients with human anti-chimeric antibody (HACA) titers may have allergic or hypersensitivity reactions when treated with other diagnostic or therapeutic monoclonal antibodies.
Potentially Fatal: Concomitant admin with thrombolytics, anticoagulants and other antiplatelet agents may result in increased bleeding.
See Below for More abciximab Drug Interactions
Mechanism of Actions
 Abciximab acts by binding to glycoprotein IIb or IIIa receptor on platelet surface thus inhibiting fibrinogen binding preventing platelet aggregation.
Absorption: Absorbed from systemic circulation (IV); peak plasma concentrations fall rapidly due to binding of free abciximab.
Distribution: Platelet receptors after IV admin.
Excretion: 15 days (elimination half-life).
Storage Conditions
 Intravenous: Refrigerate at 2-8°C.
ATC Classification
 B01AC13 - abciximab ; Belongs to the class of platelet aggregation inhibitors excluding heparin. Used in the treatment of thrombosis.
Storage
 Intravenous: Refrigerate at 2-8°C.
Available As
  • Abciximab 2 mg

    • Subscribe for latest updates

    Subscribe to our e-mail newsletter to receive updates.

    No comments yet.

    Post Review about Abciximab


    Abciximab Containing Brands

    We are Developing Our database, More results coming soon.

    Abciximab is used in following diseases

    We are Developing Our database, More results coming soon.

    Drug - Drug Interactions of Abciximab

    We are Developing Our database, More results coming soon.